Sven Eric Olsson

TL;DR: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group.

TL;DR: In this paper, a double-blind placebo-controlled phase II study was done to assess the efficacy of a prophylactic quadrivalent vaccine targeting the human papillomavirus (HPV) types associated with 70% of cervical cancers (types 16 and 18) and with 90% of genital warts (types 6 and 11).

TL;DR: High-coverage HPV vaccination programs among adolescents and young women may result in a rapid reduction of genital warts, cervical cytological abnormalities, and diagnostic and therapeutic procedures and in the longer term, substantial reductions in the rates of cervical, vulvar, and vaginal cancers may follow.

TL;DR: Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years), suggesting an anamnestic response.

TL;DR: Quadrivalent HPV vaccine provided sustained protection against low grade lesions attributable to vaccine HPV types and a substantial reduction in the burden of these diseases through 42 months of follow-up.